| 10.75 0.42 (4.07%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.56 |
1-year : | 14.67 |
| Resists | First : | 10.76 |
Second : | 12.56 |
| Pivot price | 9.45 |
|||
| Supports | First : | 9.21 |
Second : | 8.26 |
| MAs | MA(5) : | 10.18 |
MA(20) : | 9.31 |
| MA(100) : | 7.7 |
MA(250) : | 6.27 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 96.1 |
D(3) : | 92.7 |
| RSI | RSI(14): 67.6 |
|||
| 52-week | High : | 10.93 | Low : | 4.15 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ VIR ] has closed below upper band by 2.4%. Bollinger Bands are 58% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 10.77 - 10.82 | 10.82 - 10.87 |
| Low: | 10.13 - 10.19 | 10.19 - 10.24 |
| Close: | 10.65 - 10.75 | 10.75 - 10.83 |
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Thu, 16 Apr 2026
Vir Biotechnology, Inc. ($VIR) CEO 2025 Pay Revealed - Quiver Quantitative
Thu, 16 Apr 2026
Vir Biotechnology, Inc. Receives $240 Million Upfront Payment and $75 Million Equity Investment from Astellas - marketscreener.com
Thu, 16 Apr 2026
Vir Biotechnology (NASDAQ: VIR) sets 2026 meeting and pay vote - Stock Titan
Thu, 16 Apr 2026
Vir Biotechnology closes $240M Astellas deal for cancer drug - Investing.com
Thu, 16 Apr 2026
Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 160 (M) |
| Shares Float | 103 (M) |
| Held by Insiders | 9.4 (%) |
| Held by Institutions | 70.3 (%) |
| Shares Short | 15,440 (K) |
| Shares Short P.Month | 12,780 (K) |
| EPS | -3.17 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.48 |
| Profit Margin | 0 % |
| Operating Margin | -75 % |
| Return on Assets (ttm) | -24.4 % |
| Return on Equity (ttm) | -45.8 % |
| Qtrly Rev. Growth | 417.7 % |
| Gross Profit (p.s.) | -2.36 |
| Sales Per Share | 0.42 |
| EBITDA (p.s.) | -2.86 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -392 (M) |
| Levered Free Cash Flow | -174 (M) |
| PE Ratio | -3.41 |
| PEG Ratio | 0 |
| Price to Book value | 1.95 |
| Price to Sales | 25.05 |
| Price to Cash Flow | -4.39 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|